MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
DENTSPLY SIRONA EBITDA 2011-2026 | XRAY
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA DENTSPLY SIRONA
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -70 M | -530 M | 258 M | -609 M | 955 M | 331 M | 676 M | 680 M | 830 M | 750 M | 563 M | 586 M | 560 M | 537 M | 422 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 955 M | -609 M | 396 M |
Quarterly EBITDA DENTSPLY SIRONA
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -126 M | -40 M | 142 M | - | -373 M | 136 M | 128 M | - | - | - | 29 M | - | -1.13 B | 178 M | 126 M | - | 226 M | 218 M | 182 M | - | 186 M | -39 M | -93 M | 137 M | 211 M | 138 M | 82.2 M | 81.8 M | 149 M | -1.09 B | 102 M | -706 M | 202 M | -986 M | 115 M | 134 M | 214 M | 176 M | 96.2 M | 93.1 M | 160 M | 125 M | 117 M | 103 M | 173 M | 169 M | 127 M | 97.4 M | 167 M | 165 M | 114 M | - | 148 M | 149 M | 107 M | - | 86.9 M | 129 M | 114 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 226 M | -1.13 B | 23.1 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical instruments industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Masimo Corporation
MASI
|
-164 M | $ 178.51 | 0.04 % | $ 9.51 B |  USA |
 |
Merit Medical Systems
MMSI
|
308 M | $ 68.14 | 0.01 % | $ 4.03 B | USA |
 |
ICU Medical
ICUI
|
244 M | $ 129.83 | -0.08 % | $ 3.2 B | USA |
 |
Luminex Corporation
LMNX
|
72.9 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
-12.3 M | - | -9.52 % | $ 20.6 M | USA |
 |
Atrion Corporation
ATRI
|
37.7 K | - | - | $ 810 M | USA |
 |
Envista Holdings Corporation
NVST
|
332 M | $ 26.2 | 1.43 % | $ 4.4 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
-11.8 M | $ 11.0 | 3.77 % | $ 26.7 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
16.2 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
123 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
33.9 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
518 M | - | -0.05 % | $ 10.3 B | USA |
 |
OraSure Technologies
OSUR
|
-61.8 M | $ 3.13 | 1.46 % | $ 230 M | USA |
 |
Varian Medical Systems, Inc.
VAR
|
60 M | - | -0.02 % | $ 16.3 B | USA |
 |
Nephros
NEPH
|
-1.38 M | $ 3.1 | -0.48 % | $ 32.2 M | USA |
 |
Haemonetics Corporation
HAE
|
337 M | $ 57.27 | -2.05 % | $ 2.88 B | USA |
 |
Baxter International
BAX
|
673 M | $ 16.66 | 0.18 % | $ 8.55 B | USA |
 |
Pro-Dex
PDEX
|
11.9 M | $ 50.22 | 4.73 % | $ 165 M | USA |
 |
Pulse Biosciences
PLSE
|
-76.5 M | $ 21.19 | 1.24 % | $ 1.43 B | USA |
 |
Isoray
ISR
|
-110 M | - | 0.03 % | $ 108 M | USA |
 |
AngioDynamics
ANGO
|
-14.2 M | $ 10.53 | -1.68 % | $ 430 M | USA |
 |
Intuitive Surgical
ISRG
|
3.55 B | $ 471.39 | -1.39 % | $ 168 B | USA |
 |
AtriCure
ATRC
|
2.64 M | $ 29.48 | -1.01 % | $ 1.41 B | USA |
 |
InfuSystem Holdings
INFU
|
15 M | $ 9.5 | -1.04 % | $ 196 M | USA |
 |
iRhythm Technologies
IRTC
|
-36.7 M | $ 118.47 | 0.28 % | $ 3.79 B | USA |
 |
Repligen Corporation
RGEN
|
116 M | $ 116.73 | 0.32 % | $ 6.5 M | USA |
 |
BioLife Solutions
BLFS
|
-1.97 M | $ 19.73 | 2.92 % | $ 909 M | USA |
 |
Milestone Scientific
MLSS
|
-6.72 M | $ 0.29 | 3.18 % | $ 23.1 M | USA |
 |
electroCore
ECOR
|
-12.7 M | $ 6.1 | -0.57 % | $ 51.7 K | USA |
 |
STERIS plc
STE
|
1.34 B | $ 223.91 | 1.29 % | $ 22.1 B | USA |
 |
The Cooper Companies
COO
|
1.06 B | $ 70.44 | 0.28 % | $ 14 B | USA |
 |
Teleflex Incorporated
TFX
|
192 M | $ 107.37 | 1.44 % | $ 4.79 B | USA |
 |
Predictive Oncology
POAI
|
-10.8 M | - | - | $ 31.1 M | USA |
 |
Glaukos Corporation
GKOS
|
-95 M | $ 105.97 | -0.81 % | $ 5.13 B | USA |
 |
Utah Medical Products
UTMD
|
17.4 M | $ 64.81 | -0.49 % | $ 235 M | USA |
 |
West Pharmaceutical Services
WST
|
756 M | $ 247.32 | 2.37 % | $ 17.9 B | USA |
 |
ResMed
RMD
|
1.16 B | $ 230.2 | 0.95 % | $ 33.6 B | USA |
 |
Microbot Medical
MBOT
|
-9.75 M | $ 2.49 | -1.24 % | $ 25.4 M |  Israel |
 |
Retractable Technologies
RVP
|
-13.5 M | $ 0.7 | -3.33 % | $ 21 M | USA |
 |
NeuroMetrix
NURO
|
-8.69 M | - | 5.05 % | $ 9.02 M | USA |
 |
STAAR Surgical Company
STAA
|
-83.4 M | $ 19.24 | 3.94 % | $ 954 M | USA |
 |
Stereotaxis
STXS
|
-21.5 M | $ 1.79 | -2.99 % | $ 163 M | USA |
 |
Becton, Dickinson and Company
BDX
|
5.04 B | $ 156.23 | 0.01 % | $ 44.9 B | USA |
 |
Harvard Bioscience
HBIO
|
-46.8 M | $ 5.19 | -2.81 % | $ 230 M | USA |
 |
Repro Med Systems
KRMD
|
-2.16 M | $ 4.4 | -0.68 % | $ 203 M | USA |
 |
LeMaitre Vascular
LMAT
|
78.3 M | $ 109.27 | 1.31 % | $ 2.47 B | USA |
 |
Alcon
ALC
|
580 M | $ 74.18 | 0.08 % | $ 40.4 B |  Schweiz |